Healthcare Sales & Marketing Network News: oxaliplatin

Searching News Database: oxaliplatin

HSMN NewsFeed - 9 Jun 2023
Astellas Submits New Drug Application for Zolbetuximab in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 May 2021
FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Feb 2019
FDA Approves Taiho Oncology's LONSURF(R) (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Oct 2018
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi(R) in Combination with Nivolumab in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Sep 2018
Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Aug 2017
ARMO BioSciences Raises $67 Million in a Series C-1 Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Nov 2016
Athenex and Lilly Enter Clinical Collaboration Agreement
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Apr 2016
Taiho's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Phase III TERRA Study in Asian Patients with Refractory Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Mar 2016
Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat(R) Against Nippon Kayaku Co., Ltd.
Biopharmaceuticals Generics Oncology Litigation

HSMN NewsFeed - 29 Feb 2016
CHMP Issues Positive Opinion for LONSURF(R) (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Feb 2016
SIRFLOX Study Published in Journal of Clinical Oncology
Devices Interventional Radiology Oncology

HSMN NewsFeed - 6 Apr 2015
European Commission Approves Amgen's Vectibix(R) (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Mar 2015
Sirtex Reports Preliminary SIRFLOX Study Results
Devices Drug Delivery Oncology

HSMN NewsFeed - 13 Oct 2014
FDA Approves AKYNZEO(R) (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Aug 2014
FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Feb 2014
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Dec 2013
European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Oct 2013
Health Canada Approves A New Treatment Option For Patients With Gastrointestinal Stromal Tumours (GIST), A Rare Form Of Sarcoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 1 Oct 2013
Genomic Health Announces Presentation of Oncotype DX(R) Studies Reinforcing Value of Tests in Guiding Treatment for Multiple Cancers
Diagnostics Oncology

HSMN NewsFeed - 30 Aug 2013
Bayer's Stivarga(R) (regorafenib) Tablets Approved in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Feb 2013
ZALTRAP(R) (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Oct 2012
Bayer's Stivarga(R) (regorafenib) Tablets New Drug Application Granted Priority Review by U.S. FDA for the Treatment of Patients with Gastrointestinal Stromal Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Aug 2012
Hospira Announces U.S. Re-Launch Of Generic Oxaliplatin Injection
Biopharmaceuticals Generics Oncology

HSMN NewsFeed - 5 Apr 2012
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP(R) (aflibercept)
Biopharmaceuticals

HSMN NewsFeed - 6 Jun 2011
ZALTRAP (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Mar 2011
Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Mar 2011
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Jun 2010
APP Pharmaceuticals to Market Oxaliplatin Injection (Liquid) in the U.S.
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Apr 2010
Genta's Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Apr 2010
Par Pharmaceutical Enters Into Agreement With sanofi-aventis to Settle Patent Litigation Over Generic Eloxatin(R)
Biopharmaceuticals Generics Oncology Litigation

HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Apr 2010
Teva Settles Generic Eloxatin Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 29 Mar 2010
Merck Serono: Erbitux Granted Extended Use in Japan for 1st-Line Treatment of mCRC Patients with KRAS Wild-Type Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Jan 2010
Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Nov 2009
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Sep 2009
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Sep 2009
Data Presented from Two Phase 3 ERBITUX(R) Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Sep 2009
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Aug 2009
Teva Announces Approval and Launch of Oxaliplatin Injection
Biopharmaceuticals Generics Oncology FDA

HSMN NewsFeed - 11 Aug 2009
Hospira Launches Generic Oxaliplatin Injection
Biopharmaceuticals Generics Oncology FDA

HSMN NewsFeed - 20 Jul 2009
ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX(R) (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Jun 2009
Hospira Receives Favorable Court Decision on Eloxatin(R)
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 1 Jun 2009
Randomized Controlled Trial of Radioactive Resin Microspheres Demonstrates Significant Delay in Progression of Disease in Patients with Colorectal Cancer Liver Metastases who have Exhausted Chemotherapy
Biopharmaceuticals Oncology Gastroenterology

HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Apr 2009
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Mar 2009
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Jan 2009
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jan 2009
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Oct 2008
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Oct 2008
Pfizer Names New Head of Clinical Development and Medical Affairs for Its Oncology Business Unit
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 20 Oct 2008
Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 19 Sep 2008
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Sep 2008
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Sep 2008
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Jul 2008
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jul 2008
ImClone Announces Changes in Commercial Organization Leadership
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Jun 2008
ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2008
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2008
Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 May 2008
New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 May 2008
ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Mar 2008
Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Mar 2008
Pro-Pharmaceuticals DAVANAT(R) Extends Median Survival 6.7 Months for End-Stage Colorectal Cancer Patients After All Other Treatments Failed
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Feb 2008
New Data Shows DAVANAT(R) Extends Survival of End-Stage Colorectal Cancer Patients More Than 6 Months
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Feb 2008
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates
Biopharmaceuticals Licensing

HSMN NewsFeed - 24 Jan 2008
KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Jan 2008
Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
Biopharmaceuticals Generics

HSMN NewsFeed - 7 Jan 2008
Xeloda(R) Combination Therapy in Esophagogastric Cancer Highlighted in New England Journal of Medicine
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Dec 2007
Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Nov 2007
Published Data Suggest That ERBITUX(R) Enables Complete Surgical Resection of Colorectal Liver Metastases in Patients Previously Refractory to Conventional Systemic Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Nov 2007
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Oct 2007
ImClone and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Oct 2007
Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Sep 2007
New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical Response
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Sep 2007
Pro-Pharmaceuticals Names Theodore Zucconi, Ph.D., President; Nominated to the Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Sep 2007
Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 Aug 2007
Review Examines the Use of Sirtex's SIR-Spheres(R) Microspheres in Patients with Hepatic Colorectal Cancer Metastases
Devices Oncology

HSMN NewsFeed - 9 Jul 2007
Pro-Pharmaceuticals Updates Progress of Clinical Trials & DAVANAT(R) 505 (b)(2) Filings
Biopharmaceuticals Oncology Drug Delivery

HSMN NewsFeed - 25 Jun 2007
GPC Biotech Announces Partnering Agreement for Satraplatin for Japan with Yakult
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 18 Jun 2007
Health Canada approves new chemotherapy treatment for patients with metastatic colorectal cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Jun 2007
FDA Accepts and Grants Priority Review of ERBITUX(R) (Cetuximab) sBLA for Overall Survival in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Eloxatin(R) (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 May 2007
Amgen to Appeal CHMP Opinion on Vectibix(TM) (Panitumumab)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 May 2007
NCCN Updates Esophageal and Gastric Cancer Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Apr 2007
Access Pharmaceuticals Announces Expansion of ProLindac(TM) Clinical Trial Sites
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Apr 2007
Pro-Pharmaceuticals Issues Corporate Update
Biopharmaceuticals

HSMN NewsFeed - 16 Apr 2007
Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Apr 2007
Pro-Pharmaceuticals Plans to Submit a New Drug Application for DAVANAT(R), as a Functional Excipient, with 5-FU to Treat Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Apr 2007
Pro-Pharmaceuticals Receives Letter from the FDA for New Drug Application for DAVANAT(R)/ 5-FU
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Apr 2007
Pro-Pharmaceuticals Announces Tampa General Hospital Dosing Patients with DAVANAT(R)/5-FU in Phase II, First Line, Advanced Biliary Cancer Clinical Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Mar 2007
Roche Submits Application to the FDA for use of XELOX (Xeloda(R) plus oxaliplatin) With or Without Avastin(R) for the Treatment of Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Mar 2007
Amgen Discontinues Vectibix(TM) Treatment in Pacce Trial Evaluating Vectibix(Tm) as Part of Triple Combination Regimen
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Mar 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa(TM) in Brain Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Feb 2007
Pro-Pharmaceuticals Submits Orphan Drug Status Application to European Medicines Agency Co-administration of DAVANAT(R) with 5-FU to Treat Cholangiocarcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Feb 2007
Pro-Pharmaceuticals Meeting Scheduled with the FDA
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Feb 2007
Access Pharmaceuticals Appoints Esteban Cvitkovic, M.D. as Director and Vice Chairman (Europe)
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Feb 2007
Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of DAVANAT(R) with 5-FU in Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jan 2007
NCCN Updates Colon Cancer Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jan 2007
Results Show XELOX (Xeloda(R) plus oxaliplatin) Provides Equivalent Overall Patient Survival Compared to FOLFOX in Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
Xeloda(R) Combination Meets Primary Endpoint in International Phase III Advanced Colorectal Cancer Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Oct 2006
Dako Receives FDA Approval for Use of EGFR pharmDx(TM) With Vectibix(TM)
Diagnostics FDA Oncology

HSMN NewsFeed - 2 Oct 2006
XELOX (Xeloda(R) + oxaliplatin) Shown to be as Effective as Current Standard in the Treatment of Advanced Colorectal Cancer for Progression-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Sep 2006
FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Sep 2006
Poniard Pharmaceuticals Expands Picoplatin Agreement to Include Exclusive Worldwide Rights and Improved Financial Terms and Conditions
Biopharmaceuticals Licensing

HSMN NewsFeed - 29 Jun 2006
ADVENTRX Presents Encouraging New Supplemental Results for the CoFactor Phase II Metastatic Colorectal Cancer Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 May 2006
Recruitment Planned to Resume in AVANT International Phase III Trial in Adjuvant Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 May 2006
Sirtex Announces Clinical Trial Evaluating the Use of SIR-Spheres(R) Microspheres with Xeloda(R) for Metastatic Liver Cancer
Devices Biopharmaceuticals Oncology

Return to NewsFeed

Additional items found! 92

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 92 additional stories matching:
oxaliplatin
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.